Pyxis Oncology elects directors, ratifies 2026 auditor
Pyxis Oncology, Inc. held its Annual Meeting of Stockholders in virtual format on June 15, 2026.
Rhea-AI Filing Summary
Pyxis Oncology, Inc. held its Annual Meeting of Stockholders in virtual format on June 15, 2026. As of the April 20, 2026 record date, 62,855,464 shares of common stock were outstanding and entitled to vote. A quorum was present, with 47,302,035 shares represented virtually, in person or by proxy.
Stockholders elected three Class II directors—Thomas Civik, Freda Lewis-Hall, M.D., and Michael A. Metzger—to serve until the 2029 annual meeting and until their successors are elected and qualified. Support levels varied by nominee, with for votes ranging from 19,188,755 to 27,341,415.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,203,257 votes for, 1,076,997 against and 21,781 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding entitled to vote: 62,855,464 shares
Shares present for quorum: 47,302,035 shares
Votes for auditor ratification: 46,203,257 votes
+5 more
8 metrics
Shares outstanding entitled to vote
62,855,464 shares
Common stock as of record date April 20, 2026
Shares present for quorum
47,302,035 shares
Represented at annual meeting establishing quorum
Votes for auditor ratification
46,203,257 votes
In favor of Ernst & Young LLP for fiscal year 2026
Votes against auditor ratification
1,076,997 votes
Opposed Ernst & Young LLP appointment for 2026
Abstentions on auditor ratification
21,781 votes
Abstain votes on ratifying Ernst & Young LLP
Votes for Thomas Civik
27,341,415 votes
Election as Class II director
Votes for Freda Lewis-Hall, M.D.
19,188,755 votes
Election as Class II director
Votes for Michael A. Metzger
26,521,575 votes
Election as Class II director
Key Terms
Annual Meeting of Stockholders, record date, quorum, broker non-votes, +2 more
6 terms
Annual Meeting of Stockholders financial
"On June 15, 2026, Pyxis Oncology, Inc. held its Annual Meeting of Stockholders at 10:00 a.m."
record date financial
"As of April 20, 2026, the Company’s record date, there were a total of 62,855,464 shares"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
quorum financial
"47,302,035 shares of common stock were present ... and, therefore, a quorum was present."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"Votes were cast as follows ... Broker Non-Votes 17,978,763"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company Item 5.07. Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pyxis Oncology (PYXS) stockholders vote on at the 2026 annual meeting?
Stockholders voted on two key items: electing three Class II directors and ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Were Pyxis Oncology’s Class II director nominees elected at the 2026 annual meeting?
Yes. Thomas Civik, Freda Lewis-Hall, M.D., and Michael A. Metzger were elected as Class II directors to serve until the 2029 annual meeting and until their successors are elected and qualified.
How did Pyxis Oncology (PYXS) stockholders vote on the auditor ratification in 2026?
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for 2026, with 46,203,257 votes for, 1,076,997 against, and 21,781 abstentions, and no broker non-votes reported on this proposal.
What were the vote totals for Pyxis Oncology director nominee Thomas Civik?
Thomas Civik received 27,341,415 votes for and 1,981,857 votes withheld, with 17,978,763 broker non-votes recorded on the director election proposal at the 2026 annual meeting.
How many broker non-votes occurred on Pyxis Oncology’s 2026 director elections?
For each of the three Class II director nominees, there were 17,978,763 broker non-votes recorded on the election proposal at the 2026 annual meeting of stockholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
